- Home
- HALO vs CORT Comparison
HALO vs CORT Comparison
Compare HALO & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HALO | CORT |
|---|---|---|
| Founded | 1998 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 7.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HALO | CORT |
|---|---|---|
| Price | $62.28 | $88.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | $73.33 | ★ $139.00 |
| AVG Volume (30 Days) | ★ 2.4M | 663.7K |
| Earning Date | 11-03-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.68 | N/A |
| EPS | ★ 4.74 | 0.87 |
| Revenue | ★ $1,242,852,000.00 | $741,172,000.00 |
| Revenue This Year | $34.83 | $23.79 |
| Revenue Next Year | $24.84 | $40.97 |
| P/E Ratio | ★ $13.14 | $99.75 |
| Revenue Growth | ★ 31.19 | 17.92 |
| 52 Week Low | $46.26 | $49.00 |
| 52 Week High | $79.50 | $117.33 |
Technical Indicators
Market Signals| Indicator | HALO | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 34.09 | 68.54 |
| Support Level | $61.23 | $81.31 |
| Resistance Level | $63.26 | $87.19 |
| Average True Range (ATR) | 2.42 | 2.86 |
| MACD | -0.79 | 0.74 |
| Stochastic Oscillator | 7.60 | 93.81 |
Price Performance
Historical ComparisonAbout HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.